ATP1A2 Gene

ATP1A2 Gene — Sodium/Potassium ATPase Alpha-2 Subunit

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATP1A2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATP1A2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATPase Na⁺/K⁺ Transporting Subunit Alpha 2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1q21.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>476</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>182340</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000118520</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P13637 (also P24720 isoform)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>1018 amino acids</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding</td>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Primary Expression</td>
</tr>
<tr>
<td class="label">ATP1A1</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td class="label">ATP1A2</td>
<td>Brain (astrocytes)</td>
</tr>
<tr>
<td class="label">ATP1A3</td>
<td>Brain (neurons)</td>
</tr>
<tr>
<td class="label">ATP1A4</td>
<td>Testis</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2 edges</a></td>
</tr>
</table>

Overview

ATP1A2 Gene — Sodium/Potassium ATPase Alpha-2 Subunit

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATP1A2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ATP1A2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATPase Na⁺/K⁺ Transporting Subunit Alpha 2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>1q21.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>476</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>182340</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000118520</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P13637 (also P24720 isoform)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>1018 amino acids</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding</td>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Primary Expression</td>
</tr>
<tr>
<td class="label">ATP1A1</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td class="label">ATP1A2</td>
<td>Brain (astrocytes)</td>
</tr>
<tr>
<td class="label">ATP1A3</td>
<td>Brain (neurons)</td>
</tr>
<tr>
<td class="label">ATP1A4</td>
<td>Testis</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2 edges</a></td>
</tr>
</table>

Overview

The ATP1A2 gene encodes the alpha-2 (alpha2) subunit of the Na+/K+-ATPase, a fundamental membrane enzyme that maintains the electrochemical gradients essential for cellular function. The Na+/K+-ATPase uses ATP to pump three sodium ions out of the cell and two potassium ions into the cell, creating gradients that are critical for neuronal excitability, secondary active transport, cell volume regulation, and resting membrane potential maintenance. While the alpha-1 subunit (ATP1A1) is ubiquitously expressed, the alpha-2 isoform (ATP1A2) shows a highly restricted expression pattern with particularly high levels in the brain, especially in [astrocytes](/entities/astrocytes). This astrocyte-specific expression makes ATP1A2 uniquely important for astrocyte-neuron interactions, including potassium buffering, glutamate clearance, calcium signaling, and metabolic support of [neurons](/entities/neurons). Mutations in ATP1A2 have been directly linked to familial hemiplegic migraine type 2 (FHM2), epilepsy, and more recently implicated in amyotrophic lateral sclerosis (ALS). The gene's dysfunction leads to impaired neuronal excitability, disrupted calcium homeostasis, and altered intracellular signaling, all of which are central features of neurodegenerative disease pathogenesis. Located on chromosome 1q21.3, ATP1A2 represents a critical node linking astrocyte function to neuronal survival in health and disease.

Regional Brain Expression

[Allen Human Brain Atlas — ATP1A2 Expression](https://human.brain-map.org/microarray/search/show?search_term=ATP1A2): Highest expression in cortical regions, thalamus, and brainstem. Astrocyte-specific enrichment confirmed via single-cell RNA-seq datasets. Regional vulnerability patterns align with ATP1A2 dysfunction in migraine with aura and ALS. [[@blanco2019]](https://pubmed.ncbi.nlm.nih.gov/30851891/) [[@sweadner2020]](https://pubmed.ncbi.nlm.nih.gov/31928954/)

Gene Information

The Na⁺/K⁺-ATPase Enzyme

The Na⁺/K⁺-ATPase is a P-type ATPase that belongs to a family of ion pumps that transport cations across cellular membranes using ATP hydrolysis. The enzyme is composed of multiple subunits:

Subunit Composition

• Alpha subunit (catalytic): The largest subunit (~1000 amino acids) that contains the ATP-binding site, ion binding sites, and performs the actual pumping cycle. Four isoforms exist (ATP1A1-ATP1A4), with different tissue distributions.
• Beta subunit: Required for proper membrane insertion and enzyme stability
• Gamma subunit (FXYD2): Modulates enzyme activity and regulates its affinity for sodium

Structure and Mechanism

• N-domain: ATP-binding region
• P-domain: Phosphorylation site (Asp369) during the transport cycle
• A-domain: Actuator domain that undergoes conformational changes
• Transmembrane domains: 10 transmembrane helices forming the ion channel

• Intracellular Na⁺: ~10-15 mM (low compared to extracellular ~140 mM)
• Extracellular Na⁺: ~140 mM
• Intracellular K⁺: ~140 mM (high compared to extracellular ~3-5 mM)
• Resting membrane potential: Approximately -70 mV

ATP1A2 Expression and Cell-Type Specificity

ATP1A2 exhibits a highly specific expression pattern that distinguishes it from other alpha subunit isoforms:

Brain Expression

• Astrocytes: Highest expression in perivascular and perineuronal astrocytes
• Oligodendrocytes: Lower but significant expression
• Some neuronal populations: Certain cortical and hippocampal neurons

Comparison with Other Isoforms

Regional Distribution

• Cerebral [cortex](/brain-regions/cortex) layers 1-3
• [Hippocampus](/brain-regions/hippocampus), particularly CA1 region
• [Cerebellum](/brain-regions/cerebellum) (Purkinje cells)
• Basal ganglia
• Brainstem nuclei

Astrocyte-Specific Features

• Perivascular end-feet: Adjacent to blood vessels
• Perisynaptic processes: Surrounding synapses
• Gap junction coupling: Connexin-43 positive astrocyte networks

Function in Astrocytes

Potassium Buffering

• During neuronal activity, K⁺ is released into the extracellular space
• Astrocytes take up excess K⁺ through ATP1A2 and Kir4.1 channels
• K⁺ is redistributed through the astrocyte network via gap junctions
• This buffering prevents extracellular K⁺ accumulation that could disrupt neuronal excitability

• Maintaining low extracellular K⁺ (~3 mM) during high neuronal activity
• Preventing spreading depolarization
• Supporting repeated neuronal firing

Glutamate Clearance

• EAAT1 (GLAST) and EAAT2 (GLT-1) glutamate transporters
• Na⁺ gradient driving glutamate uptake
• ATP1A2 maintains this Na⁺ gradient

• Glutamate clearance is compromised
• Excitotoxicity results from excessive glutamate
• This mechanism is particularly relevant in ALS and other excitotoxic diseases

Calcium Signaling

• Na⁺ gradient affects Na⁺/Ca²⁺ exchanger (NCX) function
• Altered Ca²⁺ signaling affects astrocyte-neuron communication
• Impaired Ca²⁺ dynamics reduce neuroprotective signaling

Metabolic Support

• Provides energy for glycogen breakdown
• Supports the astrocyte-neuron lactate shuttle
• Maintains ion homeostasis during active neurotransmission

Neurological Disease Associations

Familial Hemiplegic Migraine Type 2 (FHM2)

ATP1A2 mutations are the primary cause of FHM2, a rare autosomal dominant migraine subtype with aura including temporary paralysis on one side of the body:

Pathogenic Mechanisms:

• Mutant ATP1A2 reduces Na⁺/K⁺ pump activity
• Impaired glutamate clearance leads to cortical spreading depression
• Reduced potassium buffering contributes to neuronal hyperexcitability
• Altered intracellular Na⁺ affects voltage-gated calcium channels

• Over 40 pathogenic mutations identified
• Most are missense mutations affecting ion binding or ATP hydrolysis
• Mutations have variable penetrance and severity
• Some mutations also cause epilepsy without migraine

• Acetazolamide (carbonic anhydrase inhibitor) can be effective
• Potassium channel openers under investigation
• Gene therapy approaches being explored

Epilepsy

ATP1A2 mutations are associated with various epilepsy syndromes:

• FHM2 with epilepsy: Up to 20% of FHM2 patients have seizures
• Dravet syndrome: Some patients have ATP1A2 mutations
• Rolandic epilepsy: Association with certain ATP1A2 variants

• Impaired astrocytic potassium buffering causes neuronal hyperexcitability
• Reduced glutamate clearance leads to excitotoxicity
• Altered Na⁺/Ca²⁺ exchange affects neuronal calcium homeostasis

Amyotrophic Lateral Sclerosis (ALS)

Recent research has implicated ATP1A2 in ALS pathogenesis:

Evidence:

• Reduced ATP1A2 expression in ALS patient brain tissue and spinal cord
• ALS-associated mutations in ATP1A2 identified in some patients
• Astrocyte dysfunction is a key feature of ALS (non-cell autonomous toxicity)
• Impaired glutamate clearance is a hallmark of ALS astrocytes

• Loss of astrocytic ATP1A2 impairs glutamate uptake (via EAAT2)
• Reduced potassium buffering contributes to motor neuron excitotoxicity
• Altered astrocyte-neuron metabolic coupling
• Activated astrocytes release toxic factors

Alzheimer's Disease

While ATP1A2 is not directly mutated in AD, its function is affected:

Observations:

• Reduced Na⁺/K⁺-ATPase activity in AD brain
• ATP1A2 expression decreased in hippocampus and cortex
• Impaired astrocyte function contributes to disease progression

• Amyloid-beta directly inhibits Na⁺/K⁺-ATPase
• Tau pathology affects pump localization to astrocyte processes
• Impaired astrocyte function worsens neuronal dysfunction

Parkinson's Disease

ATP1A2 dysfunction may contribute to PD through:

• Altered astrocyte function in the substantia nigra
• Impaired potassium buffering affecting dopaminergic neurons
• Possible interaction with alpha-synuclein pathology

ATP1A2 Signaling Functions

Beyond ion transport, ATP1A2 serves as a signaling molecule:

Src Kinase Signaling

• Binding of ouabain (a specific Na⁺/K⁺-ATPase ligand) at low concentrations triggers signaling
• Activation of EGFR transactivation
• Upregulation of antioxidant responses
• Anti-apoptotic signaling through PI3K/AKT pathway

ROS Signaling

• Oxidative modifications reduce pump activity
• This creates a feedforward loop in neurodegeneration
• Antioxidants can partially protect ATP1A2 function

Interaction with Other Proteins

• Ankyrin: Membrane cytoskeleton linkage
• Na⁺/Ca²⁺ exchanger (NCX): Coupled activity
• GLUT1 (SLC2A1): Glucose transporter coordination
• AQP4: Water channel at perivascular end-feet

Therapeutic Implications

Drug Targets

Existing Therapeutics:

• Digoxin/Ouabain: Cardiotonic steroids that inhibit Na⁺/K⁺-ATPase at high doses; low-dose signaling effects being explored
• Acetazolamide: Carbonic anhydrase inhibitor, effective in some FHM2 patients

• isoform-selective activators: Compounds that specifically activate ATP1A2
• Gene therapy: Viral vector-mediated ATP1A2 delivery to brain
• Protein replacement therapy: Recombinant ATP1A2 delivery

Challenges

• Achieving sufficient brain penetration
• Balancing ion transport vs. signaling functions
• Cell-type specificity (targeting astrocytes specifically)
• Safety concerns (narrow therapeutic window for some compounds)

Regulation of ATP1A2

Transcriptional Regulation

• Developmental expression: Increases after birth, peaks in adulthood
• Activity-dependent: Neuronal activity can regulate expression
• Hormonal regulation: Thyroid hormone affects expression

Post-translational Regulation

• Phosphorylation: Multiple sites regulate activity
• Glycosylation: N-linked glycosylation affects membrane targeting
• Palmitoylation: Affects membrane localization

Pathological Regulation

• Reduced expression in AD, PD, ALS
• Reduced activity in ischemia
• Oxidative inhibition in aging

Animal Models

Transgenic Mice

• ATP1A2 knockout: Neonatal lethality (respiratory failure)
• Conditional knockout: Astrocyte-specific deletion shows epileptic activity
• FHM2 mutant mice: Recapitulate migraine phenotype
• Humanized mice: Express human ATP1A2 variants

Phenotypes

• Seizures and cortical spreading depression
• Reduced seizure threshold
• Impaired glutamate clearance
• Altered astrocyte morphology

Research Directions

Current research areas include:

Conclusion

The ATP1A2 gene encodes the alpha-2 subunit of the Na⁺/K⁺-ATPase, a critical enzyme for astrocyte function and neuronal homeostasis. Its high expression in astrocytes makes it essential for potassium buffering, glutamate clearance, calcium signaling, and metabolic support of neurons. ATP1A2 mutations cause familial hemiplegic migraine and epilepsy, while reduced function contributes to ALS, AD, and PD pathogenesis. The dual role of ATP1A2 in both ion transport and cell signaling makes it a unique therapeutic target for neurodegenerative diseases. Understanding and manipulating ATP1A2 function offers potential for developing disease-modifying treatments that address astrocyte-neuron interactions central to neurodegeneration.

See Also

• [Na+/K+ ATPase](/proteins/nak-atpase)
• [ATP1A1 Gene](/genes/atp1a1)
• [ATP1A3 Gene](/genes/atp1a3)
• [Astrocytes](/entities/astrocytes)
• [Ion Homeostasis](/mechanisms/ion-homeostasis)
• [Glutamate Transport](/mechanisms/glutamate-transport)
• [Potassium Buffering](/mechanisms/potassium-buffering)
• [Familial Hemiplegic Migraine](/diseases/familial-hemiplegic-migraine)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Epilepsy](/diseases/epilepsy)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving ATP1A2 Gene discovered through SciDEX knowledge graph analysis: